How does Hereditary Hemorrhagic Telangiectasia (HHT) affect fertility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HHT Does Not Directly Impair Fertility

HHT itself does not cause infertility or reduce fertility rates in affected individuals. The disease is an autosomal dominant vascular disorder that primarily affects blood vessels, not reproductive organs or hormonal function 1, 2.

Key Points About HHT and Reproduction

Fertility Remains Normal

  • Women and men with HHT have normal fertility rates, as the genetic mutation affects vascular endothelial cells rather than reproductive tissues 3, 4
  • The 50% inheritance risk for each child reflects the autosomal dominant pattern, not reduced conception rates 1, 2

Pregnancy Outcomes Require Careful Management

While fertility is unaffected, pregnancy in HHT women carries specific risks:

  • Miscarriage rates are approximately 20%, which is within the range of the general population 5
  • Maternal mortality is estimated at 1.0% of pregnancies in screened populations, with severe complications occurring in 2.7-6.8% of pregnancies 6
  • Most complications occur in unscreened and untreated patients, particularly in the second and third trimesters 5, 6

Critical Pregnancy Complications

The serious risks relate to arteriovenous malformations, not fertility:

  • Pulmonary AVM complications include hemothorax (most common), hemoptysis, and severe hypoxemia 5, 6
  • Hepatic AVM complications can cause high-output heart failure and hepatobiliary necrosis 6
  • Cerebral AVM rupture leading to intracranial hemorrhage has been reported 5, 6
  • Women notice increased epistaxis frequency and new telangiectases during pregnancy 5

Clinical Management Approach

Pre-Conception Counseling

  • Provide genetic counseling to all HHT patients of childbearing age about the 50% inheritance risk 1
  • Screen for arteriovenous malformations before pregnancy, particularly pulmonary, hepatic, and cerebral AVMs 6, 3
  • Explain that screened and treated HHT patients have normal life expectancy (75.9 years), comparable to controls 7

Medication Considerations Before Conception

  • Discontinue tranexamic acid several days before attempting conception (half-life 2-8 hours) 8
  • Stop androgenic anabolic steroids 2 months before conception due to risk of fetal sexual differentiation abnormalities 8
  • Continue plasma-derived C1-inhibitor if needed (though this is for hereditary angioedema, not HHT) 8

Pregnancy Monitoring

  • Classify all HHT pregnancies as high-risk regardless of symptom severity 6
  • Monitor closely in the second and third trimesters when complications peak 5, 6
  • Epidural/spinal anesthesia can be performed safely (used in 50% of deliveries without complications), though screening for spinal AVMs is theoretically prudent 5

Post-Partum Care

  • Close follow-up for at least 72 hours after delivery by staff familiar with HHT 8
  • Inform patients about increased risk of postpartum swelling and provide treatment plans 8

Common Pitfalls to Avoid

Do not confuse pregnancy risk with infertility. HHT patients conceive normally but require specialized prenatal care 5, 6.

Do not delay AVM screening until pregnancy occurs. Pre-pregnancy screening and treatment of pulmonary, hepatic, and cerebral AVMs dramatically reduces maternal morbidity and mortality 6, 7.

Do not perform liver biopsy in any HHT patient due to catastrophic hemorrhage risk from hepatic vascular malformations 8, 1.

References

Guideline

Diagnostic Approach for Hereditary Hemorrhagic Telangiectasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Autosomal Dominant Bleeding Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis.

Genetics in medicine : official journal of the American College of Medical Genetics, 2011

Research

Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.

Journal of thrombosis and haemostasis : JTH, 2010

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.